arrow
V

Vipul Jairath

alimentiv inc
H指数:59
被引数:1.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Endoscopic and histologic healing distribution and persistent rectosigmoiditis in moderate-to-severe ulcerative colitis

内镜和病理愈合分布及中度至重度溃疡性结肠炎中的持续性直肠乙状结肠炎

2026-10-210
OAAI
Epidemiology of inflammatory bowel disease in the Middle East and North Africa: a multinational, tertiary care registry (MIRAGE) study

中东和北非地区炎症性肠病的流行病学:一项跨国、三级护理登记研究(MIRAGE研究)

2026-10-050
PRE
Comparative risk of postoperative complications in ulcerative colitis patients following preoperative advanced therapies: a network meta-analysis with meta-regression

溃疡性结肠炎患者术前接受高级疗法后术后并发症的对比风险:一项包含Meta回归的网络Meta分析

2026-08-080
PRE
Time to rethink washout periods in inflammatory bowel disease clinical trials: an international Delphi consensus

是时候重新思考炎症性肠病临床试验中的清洗期:一项国际德尔菲共识

2026-05-010
PRE
IBD 2024: Charting a New Course in IBD Proceedings of the Takeda Symposium 22–23 November 2024 W Hotel, Brisbane, Queensland, Australia

IBD 2024:炎症性肠病新方向——武田研讨会 proceedings,2024年11月22–23日,澳大利亚昆士兰州布里斯班W酒店

2025-10-100
OAAI
Primary Sclerosing Cholangitis Worsens Prognosis in Patients With Inflammatory Bowel Disease: A Propensity-Matched Cohort Study

原发性硬化性胆管炎恶化炎症性肠病患者的预后:一项倾向性匹配队列研究

2025-09-080
OAAI
Mirikizumab impact on disease clearance in patients with moderately to severely active ulcerative colitis: analysis of a pre-specified LUCENT trial endpoint

Mirikizumab对中度至重度活动性溃疡性结肠炎患者疾病清除率的影响:对LUCENT试验预设终点的分析

2025-09-010
OAAI
International Magnetic Resonance Imaging Consensus for use in Luminal Crohn’s Disease Trials and Clinical Practice

国际磁共振成像共识(用于管腔克罗恩病试验和临床实践)

2025-08-270
PRE
Spatiotemporal analysis of Crohn's disease reveals PECAM2 signaling at the basis of the inflammation-to-fibrosis transition

克罗恩病的时空分析揭示了炎症-纤维化转变基础上的PECAM2信号传导

2025-08-010
OAAI